A new cell treatment for hard-to-treat autoimmune nerve diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new cell-based treatment (called HY001N) for people with certain autoimmune neurological diseases that have not responded to standard treatments. The treatment aims to reset the immune system to reduce attacks and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of these conditions: NMOSD, myasthenia gravis, CIDP, multiple sclerosis, autoimmune encephalitis, or MOG antibody disease.
- Your disease has not responded well to at least one standard treatment (like steroids, immunosuppressants, or plasma exchange).
- You have had recent flare-ups (relapses) despite treatment.
- Your organ function (kidney, liver, blood counts, heart, lungs) must be within certain ranges.
- You must be willing to stop other immunosuppressants and use effective contraception during the study and for 24 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Hear when a new Neurological Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.